Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Financial Select Sector SPDR Fund — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Financial Select Sector SPDR Fund trades at $54.92 (market cap $51.80B). The key difference: Financial Select Sector SPDR Fund is far larger — about 5.8× Kymera Therapeutics Inc. Common Stock's market cap, and Financial Select Sector SPDR Fund is more actively traded (44,049,658 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| KYMR | XLF | |
|---|---|---|
Market Cap | $8.88B | $51.80B |
Volume | 1,028,790 | 44,049,658 |
Sector | Health | — |
52-Week High | $127.31 | $58.55 |
52-Week Low | $55.80 | $47.80 |
Typical Hold Time | 0 Days | 104 Days |
Enterprise Value | $8.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLF trades at $54.82, down 0.42% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The ETF faces sector headwinds as financial stocks lag the broader market despite rising bank profits. Recent Federal Reserve stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The financial sector ETF benefits from rising interest rates but faces regulatory uncertainty and market underperformance risks. Key catalysts include Fed policy decisions and bank earnings, while political gridlock may limit legislative impacts on financial regulations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
